1 report on the safety of non-standardized allergenic extracts ronald l. rabin, md chief, laboratory...
TRANSCRIPT
1
Report on the safety of non-standardized allergenic extracts
Ronald L. Rabin, MDChief, Laboratory of Immunobiochemistry
Division of Bacterial, Parasitic and Allergenic ProductsOffice of Vaccines Research and Review
Center for Biologics Evaluation and Research, USFDA
2
Today’s presentations
• Background• Allergenics efficacy reviews
– Panel 1, 21 CFR 601.25 (1974-1979)– Panel 2, 21 CFR 601.26 (1982-1983)
• Current evaluation process (2003-2011)• Safety of allergenic extracts• Assessments• Next steps
3
Strategy of search for safety issues
• Search for safety issues related to their properties as allergens– Pubmed– Google and other lay sources– FDA Adverse Event Reporting System (AERS)
• Search for safety issues unrelated to their properties as allergens (e.g. pathogens, toxins)– Fifteen potential issues that will be addressed in this
presentation
4
Definition of Adverse Event
Any undesirable experience associated with the use of a medical product
— “associated with the use” refers to a temporal relationship
— may or may not be causally related to the product
Serious:
Death, hospitalization, life-threatening, disability, congenital anomaly and/or other serious outcome.
5
Adverse Event Reporting System (AERS)
Collects reports of AEs from: – drugs– therapeutic biologics– allergenic extracts – blood and blood products
• Does not include preventative vaccines• Data are collected through MedWatch (Form 3500 or 3500A)
• Since 1969, >4 million reports
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm
6
Adverse Event Reporting System (AERS)
Passive surveillance system– voluntary for providers, consumers to report to FDA or
manufacturers
• Mandatory for manufacturers (CFR 600.80)– Submit adverse event report within 15 days if serious and
unexpected.– Submit other reports within 1 year.– Periodic adverse experience/Safety Update Report
(Quarterly if product is <3 years old)
7
AERS: strengths of a passive surveillance system
• Open-ended for hypothesis generation
• Potential detection of new or rare adverse events
• Timeliness
• Geographic diversity
• Capability to monitor production lots
8
AERS: limitations of a passive surveillance system
• Cannot calculate incidence rates– Under-reporting– Absence of denominators
• Reporting bias – Publicity or litigation may stimulate reporting– Newer products are more likely to be reported than older ones
• No control group
• Missing and inaccurate data
• Reported diagnoses not verified
• Lack of consistent diagnostic criteria
• No reports of concomitant medications
• Low likelihood of detection of long latency events
• Often unable to assess causation
9
AERS reports are submitted through MedWatchForms 3500 (consumers) and 3500A (manufacturers)
https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm
10
Office of Biostatistics/Division of Epidemiology
• CBER/OVRR requested an analysis of AE reports in AERS for allergenic extracts
• The analysis was provided to CBER on 09 July 2010
• Analysis report authors:
– Alexis Mosquera, RN
– Craig Zinderman, MD, MPH
11
Strategy of searching AERS for this report
• Reviewed all AERS reports that identified an allergenic extract as a suspect product and received by FDA from 1987-2010.
• Each report was classified into one of 24 AE categories based on the Medical Dictionary for Regulatory Affairs (MedDRA) reaction Preferred Terms (PT).
• Reaction PT of anaphylaxis, anaphylactic reaction, or anaphylactic shock were placed in reaction category of “anaphylaxis.”
• All other AEs (e.g. edema, urticaria, hives, dyspnea, wheezing) were classified as “allergic.”
• Reaction from multiple body systems were referred to as “mixed.”
• Each report was also categorized according to the type of allergenic product: animal, dust, fungi, food, insect, mite, mold, plant, or pollen.
• Reports associated with more than one category were counted once for EACH category on the report (# reports > # patients).
12
Summary of analysis from AERS database search
• Serious AEs to allergen extracts are relatively rare; consistent with the medical literature.
• Reported AEs are not associated with any one product or class of extracts (standardized or non-standardized).
• Therefore, these AEs are associated with the procedure of immunotherapy which, when performed in accordance with generally accepted principles, is safe.
13
Summary of AERS data associated with allergenic extracts
• 195 AEs
• Gender (n = 157): 86 females (55%), 71 males (45%)
• Age: mean 39 years (range 7-83)
Reports by Year
14
Types of reactions reported to AERS
Reaction Categories
(28%) (15%)
15
Product types reported to AERS
• n = 223 (some reports indicated more than one suspect product)
(17%)(20%)
Allergenic Product Type
16
Deaths associated with allergenic extracts reported to AERS
• 15 deaths: 10 females, 5 males
• Average age: 37 years (range 9-81)
Deaths by Year
17
Reaction categories and product types in AERS death reports
Reaction Categories and Product Types in Death reports
Reaction CategoryNumber
of Reports
Product Type
Anaphylaxis 5Plant (5) Fungi (2), Unspecified (2), Food (1), Dust (1)
Allergic 5Mite (2), Mold (2), Insect (1), Allergenic extract (2)
Mixed 2 Mite (3), Insect (1)
Cardiac 1 Plant (1)
Unevaluable Event 1 Allergenic extract (1)
No Adverse Event 1 Allergenic extract (1)
Onset of symptoms known in eight reportsSeven reports were “allergic reactions.”Onset within 5 minutes: 7 reportsOnset within 20 minutes: 1 report
18
Hospitalizations associated with allergenic extracts reported to AERS
Hospitalization: 35 of the 180 non-fatal reports (19.4%)
Hospitalizations by Year
19
AERS: Hospitalization Reaction Categories
Hospitalization Reaction Categories
20
AERS: Hospitalization Suspect Products
n = 44
Hospitalization Suspect Products
21
AERS: Ingredients associated with hospitalization
Ingredient # Reports
Yellow Jacket Venom Protein 3
Wasp Venom Protein 1
Fire Ant 1
Ragweed 3
Weeds 1
Hops 1
“Grass Mix” or “Grass” 3
Tree Mix 2
Timothy Grass 1
Bluegrass Kentucky June 1
Birch 1
Flaxseed or Linseed 1
“Pollen” 2
Mold 2
Mite 6
House Dust 2
Ingredient # Reports
Cat Hair 2
Cattle Hair 1
Unspecified Ingredient 4
Allergenic Extracts 18
Lobelia 1
Lemon Balm 1
Valerian Extract 1
Calamus Oil 1
Jimson Weed 1
Honey 1
Blueberry Leaf 1
Lactobacillus acidophilus 1
not allergenicproducts
22
Literature: Reports of frequency of serious AE
Report* extracted from surveys in U.S. of fatal and near-fatal serious AE 1973-2001.The surveys were conducted through AAAAI.Fatal reactions: 76 (~1 per 2.5-3.0 x 106 injection visits)Near-fatal reactions: 273 (~1 per 1.0 x 106 injection visits)
*Bernstein, DI and Epstein T. Immunol Clin N Amer 31:241; 2011
Clinical Features Asthma Severity
23
Products with non-allergenic related potential safety issues
Monkey Dander, RhesusTransmission of simian pathogensMonkey Hair, Rhesus
Deer Hair Transmission of TSE
Dust, AutogenousPathogens
Toxins: synthetic and pathogen associated
(APAC, October, 1986)
Dust, Cotton Gin
Dust, Grain Mill
Dust, House Mixture
Dust, Mattress
Kissing Bugs Pathogen (T. cruzii)
Wormseed Calcium Oxalate crystals
Rhubarb
Toxin
Castor Bean (2)
Laburnum (Golden chain)
Bracken Fern
Mexican Tea 23
24
Summary of analysis from AERS database search
• Serious AEs to allergen extracts are relatively rare; consistent with the medical literature.
• Reported AEs are not associated with any one product or class of extracts (standardized or non-standardized).
• Therefore, these AEs are associated with the procedure of immunotherapy which, when performed in accordance with generally accepted principles, is safe.
• There are, however, 16 products with potential safety issues that are not associated with the allergenic activity of those products
25
Today’s presentations
• Background• Allergenics efficacy reviews
– Panel 1, 21 CFR 601.25 (1974-1979)– Panel 2, 21 CFR 601.26 (1982-1983)
• Current evaluation process (2003-2011)• Safety of allergenic extracts• Assessments• Next steps